Advances in cancer chemotherapy in the era of precision medicine

doi:10.3760/cma.j.cn371439-20250719-00029

Abstract

Abstract:

Chemotherapy remains the cornerstone of systemic treatment for tumors. In the era of precision medicine，gene monitoring and model prediction can monitor the response and toxicity of chemotherapy drugs and guide clinicians in choosing appropriate treatment plans. Nanotechnology delivery can reduce the toxicity and treatment resistance of chemotherapy drugs. Antibody conjugation can directly target chemotherapy drugs to tumor cells with precision，thus jointly promoting precise chemotherapy for tumors. Artificial intelligence and machine learning will further drive the development of precise chemotherapy for tumors.

Key words: Neoplasms, Precision medicine, Drug therapy

Zhang Baihong, Yue Hongyun. Advances in cancer chemotherapy in the era of precision medicine[J]. Journal of International Oncology, 2026, 53(3): 178-181.

References 39

[1]	Kuderer NM, Desai A, Lustberg MB, et al. Mitigating acute chemo-therapy-associated adverse events in patients with cancer[J]. Nat Rev Clin Oncol, 2022, 19(11): 681-697. DOI: 10.1038/s41571-022-00685-3. pmid: 36221000
[2]	Romero D. Benefit with adjuvant metronomic capecitabine in NPC[J]. Nat Rev Clin Oncol, 2021, 18(9): 542. DOI: 10.1038/s41571-021-00536-7. pmid: 34155394
[3]	Roosendaal J, Jacobs BAW, Pluim D, et al. Phase Ⅰ pharmacological study of continuous chronomodulated capecitabine treatment[J]. Pharm Res, 2020, 37(5): 89. DOI: 10.1007/s11095-020-02828-6.
[4]	Del Mastro L, Poggio F, Blondeaux E, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(12): 1571-1582. DOI: 10.1016/S1470-2045(22)00632-5.
[5]	Claessens AKM, Erdkamp FLG, Lopez-Yurda M, et al. Secondary analyses of the randomized phase Ⅲ stop&go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer[J]. Acta Oncol, 2020, 59(6): 713-722. DOI: 10.1080/0284186X.2020.1731923. pmid: 32141389
[6]	张百红, 岳红云. 肿瘤化疗药物10年[J]. 现代肿瘤医学, 2019, 27(1): 175-179. DOI: 10.3969/j.issn.1672-4992.2019.01.044.
[7]	Nikanjam M, Kato S, Allen T, et al. Novel clinical trial designs emerging from the molecular reclassification of cancer[J]. CA Cancer J Clin, 2025, 75(3): 243-267. DOI: 10.3322/caac.21880.
[8]	张百红, 岳红云. 肿瘤的精准化疗[J]. 国际肿瘤学杂志, 2017, 44(2): 133-135. DOI: 10.3760/cma.j.issn.1673-422X.2017.02.014.
[9]	Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, et al. Heterogeneity and treatment landscape of ovarian carcinoma[J]. Nat Rev Clin Oncol, 2023, 20(12): 820-842. DOI: 10.1038/s41571-023-00819-1. pmid: 37783747
[10]	Yang L, Yang J, Kleppe A, et al. Personalizing adjuvant therapy for patients with colorectal cancer[J]. Nat Rev Clin Oncol, 2024, 21(1): 67-79. DOI: 10.1038/s41571-023-00834-2.
[11]	Trepka KR, Kidder WA, Kyaw TS, et al. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity[J]. Sci Transl Med, 2025, 17(794): eadq8870. DOI: 10.1126/scitranslmed.adq8870.
[12]	Menghi F, Banda K, Kumar P, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas[J]. Sci Transl Med, 2022, 14(652): eabn1926. DOI: 10.1126/scitranslmed.abn1926.
[13]	Coussy F, El-Botty R, Château-Joubert S, et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase Ⅰ inhibitors in triple-negative breast cancers[J]. Sci Transl Med, 2020, 12(531): eaax2625. DOI: 10.1126/scitranslmed.aax2625.
[14]	Tseng YH, Tran TTM, Tsai Chang J, et al. Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer[J]. Cell Death Discov, 2025, 11(1): 26. DOI: 10.1038/s41420-025-02300-7.
[15]	Jiang TY, Cui XW, Zeng TM, et al. PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK[J]. Sci Transl Med, 2023, 15(704): eadd7464. DOI: 10.1126/scitranslmed.add7464.
[16]	Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer[J]. N Engl J Med, 2021, 385(25): 2336-2347. DOI: 10.1056/NEJMoa2108873.
[17]	Rodrigues-Ferreira S, Nehlig A, Moindjie H, et al. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy[J]. Proc Natl Acad Sci U S A, 2019, 116(47): 23691-23697. DOI: 10.1073/pnas.1910824116.
[18]	Rodriguez H, Zenklusen JC, Staudt LM, et al. The next horizon in precision oncology: proteogenomics to inform cancer diagnosis and treatment[J]. Cell, 2021, 184(7): 1661-1670. DOI: 10.1016/j.cell.2021.02.055. pmid: 33798439
[19]	张百红, 岳红云. 纳米医学在肿瘤治疗中的应用进展[J]. 实用肿瘤杂志, 2023, 38(2): 179-183. DOI:10.13267/j.cnki.syzlzz.2023.028.
[20]	Moles E, Kavallaris M. A potent targeted cancer nanotherapeutic[J]. Nat Biomed Eng, 2019, 3(4): 248-250. DOI: 10.1038/s41551-019-0390-7. pmid: 30952987
[21]	Guo S, Vieweger M, Zhang K, et al. Ultra-thermostable RNA nano-particles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy[J]. Nat Commun, 2020, 11(1): 972. DOI: 10.1038/s41467-020-14780-5.
[22]	Shen S, Xu X, Lin S, et al. A nanotherapeutic strategy to of cancer stem-like cells[J]. Nat Nanotechnol, 2021, 16(1): 104-113. DOI: 10.1038/s41565-020-00793-0.
[23]	Abbas A, Mundaca-Uribe R, Zhang L, et al. Robotic micromotors transforming oral drug administration[J]. Trends Biotechnol, 2025, 43(9): 2197-2213. DOI: 10.1016/j.tibtech.2025.03.011.
[24]	Zhang F, Li Z, Chen C, et al. Biohybrid microalgae robots: design, fabrication, materials, and applications[J]. Adv Mater, 2024, 36(3): e2303714. DOI: 10.1002/adma.202303714.
[25]	Regeni I, Bonnet S. Supramolecular approaches for the treatment of hypoxic regions in tumours[J]. Nat Rev Chem, 2025, 9(6): 365-377. DOI: 10.1038/s41570-025-00705-7. pmid: 40185999
[26]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. DOI: 10.3760/cma.j.cn371439-20240318-00061.
[27]	Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182. DOI: 10.3322/caac.21705.
[28]	Tarantino P, Ricciuti B, Pradhan SM, et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours[J]. Nat Rev Clin Oncol, 2023, 20(8): 558-576. DOI: 10.1038/s41571-023-00783-w. pmid: 37296177
[29]	Tsuchikama K, Anami Y, Ha SYY, et al. Exploring the next generation of antibody-drug conjugates[J]. Nat Rev Clin Oncol, 2024, 21(3): 203-223. DOI: 10.1038/s41571-023-00850-2. pmid: 38191923
[30]	Blanchard Z, Brown EA, Ghazaryan A, et al. PDX models for functional precision oncology and discovery science[J]. Nat Rev Cancer, 2025, 25(3): 153-166. DOI: 10.1038/s41568-024-00779-3. pmid: 39681638
[31]	Na D, Chae J, Cho SY, et al. Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts[J]. Nat Commun, 2021, 12(1): 4840. DOI: 10.1038/s41467-021-25122-4. pmid: 34376661
[32]	Yin S, Xi R, Wu A, et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy[J]. Sci Transl Med, 2020, 12(549): eaaz1723. DOI: 10.1126/scitranslmed.aaz1723.
[33]	Akhoundova D, Rubin MA. Clinical application of advanced multio-mics tumor profiling: shaping precision oncology of the future[J]. Cancer Cell, 2022, 40(9): 920-938. DOI: 10.1016/j.ccell.2022.08.011. pmid: 36055231
[34]	Montagut C, Vidal J. Liquid biopsy for precision adjuvant chemotherapy in colon cancer[J]. N Engl J Med, 2022, 386(24): 2330-2331. DOI: 10.1056/NEJMe2204625.
[35]	Alix-Panabières C, Pantel K. Advances in liquid biopsy: from exploration to practical application[J]. Cancer Cell, 2025, 43(2): 161-165. DOI: 10.1016/j.ccell.2024.11.009. pmid: 39672165
[36]	Corsi M, Maurina E, Surdo S, et al. In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensor[J]. Sci Adv, 2025, 11(16): eads0265. DOI: 10.1126/sciadv.ads0265.
[37]	Soragni A, Knudsen ES, O'Connor TN, et al. Acquired resistance in cancer: towards targeted therapeutic strategies[J]. Nat Rev Cancer, 2025, 25(8): 613-633. DOI: 10.1038/s41568-025-00824-9. pmid: 40461793
[38]	Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research[J]. Cancer Cell, 2025, 43(4): 708-727. DOI: 10.1016/j.ccell.2025.03.018. pmid: 40233719
[39]	Luo J, Solit DB. Leveraging real-world data to advance biomarker discovery and precision oncology[J]. Cancer Cell, 2025, 43(4): 606-610. DOI: 10.1016/j.ccell.2025.03.012.